Eli Lilly's most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $247.50 short call and a strike $252.50 long call offers a potential 28.53% return on risk over the next 6 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $247.50 by expiration. The full premium credit of $1.11 would be kept by the premium seller. The risk of $3.89 would be incurred if the stock rose above the $252.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders
Fri, 10 Dec 2021 11:30:00 +0000
Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders.
AstraZeneca (AZN) Gets FDA Nod for COVID Prevention Drug
Thu, 09 Dec 2021 15:53:03 +0000
With emergency approval from the FDA, AstraZeneca's (AZN) Evusheld is the first cocktail antibody drug approved in the United States to prevent COVID-19 symptoms before virus exposure.
New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients
Thu, 09 Dec 2021 15:29:00 +0000
Eli Lilly and Company (NYSE: LLY) today announced results from the CONFIDE Study (Communicating Needs and Features of IBD Experiences) that show bowel urgency – defined as the sudden or immediate need for a bowel movement – is the second most commonly reported symptom suffered by study respondents living with moderately-to-severely active ulcerative colitis (UC), regardless of whether or not they were receiving an advanced therapy (biologic or novel oral therapy). In this study, only one in four
Eli Lilly's Pipeline Strength Paints a Promising Outlook
Wed, 08 Dec 2021 16:04:13 +0000
The company is no longer cheaply valued in the market, but the outlook remains positive
UPDATE 2-China approves Brii Biosciences antibody COVID treatment
Wed, 08 Dec 2021 15:49:11 +0000
China's medical products regulator said on Wednesday it had approved the use of Brii Biosciences' neutralising antibody cocktail for COVID-19, the first treatment of its type against the virus given the go-ahead in the country. The combination of BRII-196/BRII-198 showed a 80% reduction of hospitalisation and deaths in non-hospitalised COVID-19 patients at high risk of developing severe disease, based on final results from a Phase III clinical trial, Brii said in a statement on Thursday. The medicine from a Brii subsidiary was approved to treat mild COVID-19 and the disease of “normal type” with high risk of progressing to hospitalisation or death in adults and minors aged 12-17, the National Medical Products Administration said.
Also on Market Tamer…
Follow Us on Facebook